203 related articles for article (PubMed ID: 31608326)
1. An independently validated nomogram for isocitrate dehydrogenase-wild-type glioblastoma patient survival.
Gittleman H; Cioffi G; Chunduru P; Molinaro AM; Berger MS; Sloan AE; Barnholtz-Sloan JS
Neurooncol Adv; 2019; 1(1):vdz007. PubMed ID: 31608326
[TBL] [Abstract][Full Text] [Related]
2. An independently validated survival nomogram for lower-grade glioma.
Gittleman H; Sloan AE; Barnholtz-Sloan JS
Neuro Oncol; 2020 May; 22(5):665-674. PubMed ID: 31621885
[TBL] [Abstract][Full Text] [Related]
3. An independently validated nomogram for individualized estimation of survival among patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825.
Gittleman H; Lim D; Kattan MW; Chakravarti A; Gilbert MR; Lassman AB; Lo SS; Machtay M; Sloan AE; Sulman EP; Tian D; Vogelbaum MA; Wang TJC; Penas-Prado M; Youssef E; Blumenthal DT; Zhang P; Mehta MP; Barnholtz-Sloan JS
Neuro Oncol; 2017 May; 19(5):669-677. PubMed ID: 28453749
[TBL] [Abstract][Full Text] [Related]
4. Association of Maximal Extent of Resection of Contrast-Enhanced and Non-Contrast-Enhanced Tumor With Survival Within Molecular Subgroups of Patients With Newly Diagnosed Glioblastoma.
Molinaro AM; Hervey-Jumper S; Morshed RA; Young J; Han SJ; Chunduru P; Zhang Y; Phillips JJ; Shai A; Lafontaine M; Crane J; Chandra A; Flanigan P; Jahangiri A; Cioffi G; Ostrom Q; Anderson JE; Badve C; Barnholtz-Sloan J; Sloan AE; Erickson BJ; Decker PA; Kosel ML; LaChance D; Eckel-Passow J; Jenkins R; Villanueva-Meyer J; Rice T; Wrensch M; Wiencke JK; Oberheim Bush NA; Taylor J; Butowski N; Prados M; Clarke J; Chang S; Chang E; Aghi M; Theodosopoulos P; McDermott M; Berger MS
JAMA Oncol; 2020 Apr; 6(4):495-503. PubMed ID: 32027343
[TBL] [Abstract][Full Text] [Related]
5. A Nomogram Predicts Individual Prognosis in Patients With Newly Diagnosed Glioblastoma by Integrating the Extent of Resection of Non-Enhancing Tumors.
Zhang Z; Jin Z; Liu D; Zhang Y; Li C; Miao Y; Chi X; Feng J; Wang Y; Hao S; Ji N
Front Oncol; 2020; 10():598965. PubMed ID: 33344248
[TBL] [Abstract][Full Text] [Related]
6. Prognostic importance of temozolomide-induced neutropenia in glioblastoma, IDH-wildtype patients.
Saito T; Sugiyama K; Hama S; Yamasaki F; Takayasu T; Nosaka R; Muragaki Y; Kawamata T; Kurisu K
Neurosurg Rev; 2018 Apr; 41(2):621-628. PubMed ID: 28887717
[TBL] [Abstract][Full Text] [Related]
7. Prognostic analysis and nomogram construction for older patients with IDH-wild-type glioblastoma.
Cao W; Xiong L; Meng L; Li Z; Hu Z; Lei H; Wu J; Song T; Liu C; Wei R; Shen L; Hong J
Heliyon; 2023 Jul; 9(7):e18310. PubMed ID: 37519736
[TBL] [Abstract][Full Text] [Related]
8. Predictive value of MGMT promoter methylation on the survival of TMZ treated
Chai R; Li G; Liu Y; Zhang K; Zhao Z; Wu F; Chang Y; Pang B; Li J; Li Y; Jiang T; Wang Y
Cancer Biol Med; 2021 Feb; 18(1):272-282. PubMed ID: 33628600
[TBL] [Abstract][Full Text] [Related]
9. Independently validated sex-specific nomograms for predicting survival in patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825.
Patil N; Somasundaram E; Waite KA; Lathia JD; Machtay M; Gilbert MR; Connor JR; Rubin JB; Berens ME; Buerki RA; Choi S; Sloan AE; Penas-Prado M; Ashby LS; Blumenthal DT; Werner-Wasik M; Hunter GK; Flickinger JC; Wendland MM; Panet-Raymond V; Robins HI; Pugh SL; Mehta MP; Barnholtz-Sloan JS
J Neurooncol; 2021 Dec; 155(3):363-372. PubMed ID: 34761331
[TBL] [Abstract][Full Text] [Related]
10. IDH mutation and MGMT promoter methylation are associated with the pseudoprogression and improved prognosis of glioblastoma multiforme patients who have undergone concurrent and adjuvant temozolomide-based chemoradiotherapy.
Li H; Li J; Cheng G; Zhang J; Li X
Clin Neurol Neurosurg; 2016 Dec; 151():31-36. PubMed ID: 27764705
[TBL] [Abstract][Full Text] [Related]
11. Development and external validation of a clinical prediction model for survival in patients with IDH wild-type glioblastoma.
Mijderwijk HJ; Nieboer D; Incekara F; Berger K; Steyerberg EW; van den Bent MJ; Reifenberger G; Hänggi D; Smits M; Senft C; Rapp M; Sabel M; Voss M; Forster MT; Kamp MA
J Neurosurg; 2022 Oct; 137(4):914-923. PubMed ID: 35171829
[TBL] [Abstract][Full Text] [Related]
12. A nomogram for individualized prediction of overall survival in patients with newly diagnosed glioblastoma: a real-world retrospective cohort study.
Kudulaiti N; Zhou Z; Luo C; Zhang J; Zhu F; Wu J
BMC Surg; 2021 May; 21(1):238. PubMed ID: 33957923
[TBL] [Abstract][Full Text] [Related]
13. Multi-institutional external validation of a novel glioblastoma prognostic nomogram incorporating MGMT methylation.
Molitoris JK; Rao YJ; Patel RA; Kane LT; Badiyan SN; Gittleman H; Barnholtz-Sloan JS; Bentzen SM; Kruser TJ; Huang J; Mehta MP
J Neurooncol; 2017 Sep; 134(2):331-338. PubMed ID: 28643151
[TBL] [Abstract][Full Text] [Related]
14. O
Alassiri AH; Alkhaibary A; Al-Sarheed S; Alsufani F; Alharbi M; Alkhani A; Aloraidi A
Ann Saudi Med; 2019; 39(6):410-416. PubMed ID: 31804140
[TBL] [Abstract][Full Text] [Related]
15. Temozolomide for patients with wild-type isocitrate dehydrogenase (IDH) 1 glioblastoma using propensity score matching.
Tunthanathip T; Sangkhathat S
Clin Neurol Neurosurg; 2020 Apr; 191():105712. PubMed ID: 32036239
[TBL] [Abstract][Full Text] [Related]
16. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
[TBL] [Abstract][Full Text] [Related]
17. DGKI methylation status modulates the prognostic value of MGMT in glioblastoma patients treated with combined radio-chemotherapy with temozolomide.
Etcheverry A; Aubry M; Idbaih A; Vauleon E; Marie Y; Menei P; Boniface R; Figarella-Branger D; Karayan-Tapon L; Quillien V; Sanson M; de Tayrac M; Delattre JY; Mosser J
PLoS One; 2014; 9(9):e104455. PubMed ID: 25233099
[TBL] [Abstract][Full Text] [Related]
18. Differential Predictors and Clinical Implications Associated With Long-Term Survivors in IDH Wildtype and Mutant Glioblastoma.
Jiang H; Yu K; Cui Y; Ren X; Li M; Zhang G; Yang C; Zhao X; Zhu Q; Lin S
Front Oncol; 2021; 11():632663. PubMed ID: 34055603
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of O6-methylguanine-DNA-methyltransferase (MGMT) promoter methylation and isocitrate dehydrogenase-1 (IDH-1) mutation in glioblastoma multiforme patients: A single-center experience in the Middle East region.
Ayoub Z; Geara F; Najjar M; Comair Y; Khoueiry-Zgheib N; Khoueiry P; Mahfouz R; Boulos FI; Kamar FG; Andraos T; Saadeh F; Kreidieh F; Abboud M; Skaf G; Assi HI
Clin Neurol Neurosurg; 2019 Jul; 182():92-97. PubMed ID: 31108342
[TBL] [Abstract][Full Text] [Related]
20. Arterial spin labeling perfusion-weighted imaging aids in prediction of molecular biomarkers and survival in glioblastomas.
Yoo RE; Yun TJ; Hwang I; Hong EK; Kang KM; Choi SH; Park CK; Won JK; Kim JH; Sohn CH
Eur Radiol; 2020 Feb; 30(2):1202-1211. PubMed ID: 31468161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
